# Single Ascending Dose Study of ANX105

> **NCT05288881** · PHASE1 · COMPLETED · sponsor: **Annexon, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** ANX105
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05288881
- **Lead sponsor:** Annexon, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-28
- **Primary completion:** 2023-06-19
- **Final completion:** 2023-06-19
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05288881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05288881, "Single Ascending Dose Study of ANX105". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05288881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*